Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02568449 · ClinicalTrials.gov registry record · Phase 2
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02568449 is a Phase 2 study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 20 participants.
The verdict
NCT02568449, a Phase 2 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase II trial studies how well nintedanib works in treating patients with malignant pleural mesothelioma that has come back. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-03-15 |
| Est. Completion | 2018-06-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02568449
The ClinicalTrials.gov registry entry for NCT02568449 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nintedanib is the first listed.
NCT02568449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02568449 about?
NCT02568449 is a clinical study titled "Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent". This phase II trial studies how well nintedanib works in treating patients with malignant pleural mesothelioma that has come back. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT02568449?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-03-15. Estimated completion is 2018-06-26.
What interventions are being tested in trial NCT02568449?
The interventions under investigation include: Nintedanib (DRUG).
Who is sponsoring clinical trial NCT02568449?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.